Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
This article was originally published in The Pink Sheet Daily
Executive Summary
The first of two trials testing rapid and sustained relief of psychotic features, designed under special protocol assessment with FDA, will begin "immediately," Corcept says. Corlux is expected to share the same safety restrictions as Mifeprex (RU-486).
You may also be interested in...
Corcept Will Pursue Two Corlux Phase III Studies Despite Initial Negative Result
Mifepristone fails to show a benefit over placebo for treating psychotic major depression in the first of three trials.
Corcept Will Pursue Two Corlux Phase III Studies Despite Initial Negative Result
Mifepristone fails to show a benefit over placebo for treating psychotic major depression in the first of three trials.
Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression
Company expects data from three Phase III trials of mifepristone for PMD by year-end.